Respiratory Syrup Franchise in Ahmedabad

Cufsniff BR Plus Syrup Supplier in Mumbai

Expectorant & Bronchodilator Syrup Distributor in Delhi

Bromhexine Guaifenesin Syrup Manufacturer in Bangalore

Cough & Bronchospasm Relief Syrup Stockist in Hyderabad
Respiratory Therapy Syrup Exporter in Chandigarh

Home/Products /bromhexine-4mg-5ml-guaifenesin-50mg-terbutaline-1-25mg-5ml-syrup

Cufsniff BR Plus Syrup

Composition : Bromhexine (4mg/5ml) + Guaifenesin (50mg/5ml) + Menthol (0.5mg/5ml) + Terbutaline (1.25mg/5ml) Syrup

Dosage Form : Syrup

Packaging Type : Bottle

Packaging : 60ml

Price : ₹0/-

Cufsniff BR Plus Syrup contains Bromhexine 4 mg, Guaifenesin 50 mg, Menthol 0.5 mg, and Terbutaline 1.25 mg per 5 ml, a comprehensive respiratory combination therapy formulated to address productive cough associated with mucus retention and bronchial constriction. Bromhexine reduces mucus viscosity, enabling easier clearance from the airways.

Guaifenesin acts as an expectorant, increasing respiratory tract fluid secretion and facilitating effective expectoration, while Menthol provides a soothing and cooling effect that relieves throat irritation and cough discomfort. Terbutaline, a selective β2-agonist, relaxes bronchial smooth muscles to improve airflow.

Clinically, this formulation is indicated for acute and chronic bronchitis, productive cough, bronchospasm, and other lower respiratory tract infections where mucus accumulation and airway narrowing coexist. The synergistic action ensures rapid symptom relief and improved respiratory comfort.

The syrup formulation allows accurate dosing, fast absorption, and excellent patient compliance, making it suitable for hospitals, general practice, pediatric care, and retail pharmacies. Cufsniff BR Plus Syrup supports effective cough control, easier breathing, and faster recovery under medical supervision.

Read More

About the Product

Cufsniff BR Plus Syrup contains Bromhexine 4 mg, Guaifenesin 50 mg, Menthol 0.5 mg, and Terbutaline 1.25 mg per 5 ml, a comprehensive respiratory combination therapy formulated to address productive cough associated with mucus retention and bronchial constriction. Bromhexine reduces mucus viscosity, enabling easier clearance from the airways.

Guaifenesin acts as an expectorant, increasing respiratory tract fluid secretion and facilitating effective expectoration, while Menthol provides a soothing and cooling effect that relieves throat irritation and cough discomfort. Terbutaline, a selective β2-agonist, relaxes bronchial smooth muscles to improve airflow.

Clinically, this formulation is indicated for acute and chronic bronchitis, productive cough, bronchospasm, and other lower respiratory tract infections where mucus accumulation and airway narrowing coexist. The synergistic action ensures rapid symptom relief and improved respiratory comfort.

The syrup formulation allows accurate dosing, fast absorption, and excellent patient compliance, making it suitable for hospitals, general practice, pediatric care, and retail pharmacies. Cufsniff BR Plus Syrup supports effective cough control, easier breathing, and faster recovery under medical supervision.

Possible side effects include drowsiness, dizziness, headache, dry mouth, and gastrointestinal disturbances. Rare side effects may include allergic reactions like rash or swelling.

Cufsniff LD Syrup is indicated for the relief of dry cough, allergic rhinitis, and other symptoms associated with upper respiratory tract infections.

Consult a healthcare provider before using if pregnant or breastfeeding. Not recommended for children under 2 years.

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation